Log ind
Jan van de Winkel4.jpg
Foto: Stine Bidstrup

Genmab CEO: “Janssen is a military machine”

Top picks in English:

Janssen is pushing hard for new approvals for the Genmab-developed cancer drug Darzalex which is being tested in a range of phase III studies. This year, the biotech expects data from a trial that could clear the product for front-line use against multiple myeloma and double the potential market, says its CEO.


BY LOUISE WENDT JENSEN
Offentliggjort 29.03.17 kl. 15:02

Log ind for at læse artikler

Velkommen til MedWatch. En del af vores indhold er eksklusivt og forbeholdt vores brugere.

Prøv os gratis i 14 dage

Få fuld adgang til vores kvalitetsjournalistik med et gratis prøveabonnement.

Sign up for MedWatch newsletter
Mest læste Top picks in English

BMS signs fibrosis deal with Danish biotech company

POLFOTO_4265997.jpg Top picks in English:

A Danish biotech company is now going to develop biomarkers for US-based drug group Bristol-Myers Squibb to potentially aid in diagnosing and monitoring fibrotic diseases, including fatty liver disease NASH.

Here is what Danish drug companies pay their workers

Top picks in English:

The average monthly salary in the private pharmaceutical industry in Denmark is DKK 57,109. Make the jump to find out which company pays the highest wages and learn how much the rest of the industry pays as well.

Danish hearing aid giants in global showdown

Top picks in English:

The world’s largest hearing device dealer, Amplifon, expresses concern over the entry into the retail market of manufacturers such as William Demant. GN Resound, on the other hand, receives praise and is expected to form even closer ties to its Italian collaborator.

Danish biotech company goes courting

Top picks in English:

The small Danish biotech company Mipsalus is on the prowl for a partner to help it bring its drug to treat the hereditary metabolic condition phenylketonuria (PKU) into the clinic and onto the market as fast as possible.

Chemometec’s new growth engine could attract buyers

Top picks in English:

Chemometec is banking big on a new analysis device, scheduled for a broad launch during 2017. If the product lives up to the company’s own expectations, it could have wide-reaching consequences for the medtech company, one analyst believes.

Global venture boss keeps an eye on Danish biotech companies

Top picks in English:

Omega Funds receives 2200 applications from life science companies per year and 99.9 percent of these are turned down. But some Danish biotech companies have caught the attention of founder Otello Stampacchia and might be among the 0.1 lucky ones.

Forsiden lige nu

GSK vil revolutionere HIV-behandling

hiv.jpg Medicinal & Biotek:

Med sit mest lovende HIV-middel vil GlaxoSmithKline nu indlede et paradigmeskifte inden for HIV-behandling og reducere antallet af lægemidler, patienterne behøver at tage.

Laboratorieselskabet Holm og Halby i vækst

Medico & Rehab:

”Vi nåede næsten det samme på 9 måneder sammenlignet med 12 måneder året før,” lyder det fra en tilfreds direktør i Holm og Halby.

Medicinrådet erklærer nye fagudvalgsformænd inhabile

Medicinal & Biotek:

Den nye habilitetspolitik for Medicinrådet har spændt ben for kandidaterne til formandsposterne for to af rådets nye fagudvalg. Jagten går nu ind efter nye kandidater.

April måneds godkendelser i EMA

Medicinal & Biotek:

Det europæiske ekspertpanel CHMP havde travlt på deres aprilmøde i fredags, hvor der blev givet grønt lys for seks nye originale lægemidler og fem kopiversioner af allerede godkendte. Der var også udvidede godkendelser at hente for tre midler.

Nyt opkøb i medicobranchen til trecifret mia-beløb

Medico & Rehab:

En amerikansk Coloplast-rival er på vej til at blive solgt for 24 mia. dollars – næsten 167 mia. kr. Handlen skal godkendes af myndighederne før den kan gå endeligt igennem.

Jyske Bank hæver anbefalingen på Coloplast

Medico & Rehab:

Optimisme omkring fremtidig vækst og øgede markedsandele, får Jyske Bank til både at hæve anbefalingen og kursmålet på Coloplast. Dagens opkøb af Coloplasts amerikanske konkurrent understreger potentialet i sektoren, vurderer man hos Sydbank.

ANNONCE
ANNONCE


ANNONCE